Chemotherapy‐induced gastrointestinal symptom clusters in breast cancer impair quality of life and treatment adherence, yet lack effective interventions. While acupuncture mitigates isolated chemotherapy‐induced symptoms, its mechanisms for multi‐symptom clusters remain unclear. This study evaluates electroacupuncture's efficacy and explores its biological mechanisms in managing these clusters.

This prospective, multicenter, block‐randomized, double‐blind, sham‐controlled trial will enroll 388 patients with breast cancer undergoing neoadjuvant/adjuvant chemotherapy, to be randomly assigned (1:1) to electroacupuncture or sham electroacupuncture groups. Both groups will receive the standard quadruple antiemetic regimen combined with electroacupuncture or sham intervention. The primary endpoint is the incidence of chemotherapy‐induced gastrointestinal symptom clusters within 120 h after chemotherapy. Secondary endpoints include improvement in gastrointestinal symptom clusters post‐first chemotherapy cycle, nausea‐free rates during acute and delayed phases, vomiting‐free rates during overall, acute, and delayed phases, complete response rate, complete protection rate, and quality of life. Adverse events will be documented throughout the study.

This study will assess the efficacy and safety of electroacupuncture in alleviating chemotherapy‐induced gastrointestinal symptom clusters in patients with breast cancer. By integrating multi‐omics analyses, we aim to elucidate the biological mechanisms underlying its therapeutic effects. The findings may offer a robust clinical foundation for optimizing symptom cluster management in cancer care.

Clinical Trials ID: NCT06952920. Date of registration: April 16, 2025. Prospectively registered. URL of Trial Registry Record: https://clinicaltrials.gov/study/NCT06952920cond=NCT06952920&rank=1.

Although there have been significant advancements in the treatment modalities for gastric cancer (GC) in recent years, the overall prognosis remains poor, particularly for individuals in advanced stages. The absence of a sensitive tumor marker in GC is a crucial factor contributing to this challenge.

Our study focused on investigating a newly discovered long noncoding RNA (lncRNA) known as TCONS_00251376, which has been confirmed to exhibit differential expression in GC compared to adjacent tissues. To further validate these expression differences, we collected 22 pairs of GC and adjacent noncancerous tissues. Subsequent cell function experiments and animal studies were conducted to elucidate the role and underlying mechanisms of lncRNA TCONS_00251376 in the development of GC.

The study revealed a significant upregulation of lncRNA TCONS_00251376 in cancer tissues (p < 0.01) and a consistent upregulation in GC cell lines (AGS, MKN45, BGC‐823, and MGC‐803). Furthermore, it was observed that lncRNA TCONS_00251376 played a promotive role in the proliferation, migration, and invasion of GC cells. Subsequent analysis indicated that lncRNA TCONS_00251376 could upregulate the expression of ETV1, a factor associated with the prognosis of GC.

Therefore, our findings suggest that lncRNA TCONS_00251376 functions as an oncogenic lncRNA, promoting tumorigenesis and progression by regulating the expression of ETV1 gene. This highlights its potential as an effective target for treating GC.